; and (B) the effects of the classification of xylazine under the Controlled Substances Act ( 21 U.S.C. 801 et seq. ) on the prevalence of xylazine trafficking, misuse, and proliferation in the United States. (3) Obtaining official data The Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, may secure directly from any department or agency of the United States documents, statistical data, and other information necessary to carry out paragraphs (1) and (2). Upon receipt of a request from the Attorney General for such documents, data, and information, the head of the department or agency shall, in accordance with applicable procedures for the appropriate handling of classified information, promptly provide reasonable access to such documents, data, and information. (4) Views of experts from non-Federal entities In developing the reports under paragraphs (1) and (2), the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall consult with, and take into consideration the views of, experts from appropriate non-Federal entities, including such experts from— (A) the scientific and medical research community; (B) the State and local law enforcement community; and (C) community-based organizations. 204. Technical corrections Effective as if included in the enactment of Public Law 117–328 — (1) section 1252(a) of division FF of Public Law 117–328 is amended, in the matter being inserted into section 302(e) of the Controlled Substances Act, by striking 303(g) and inserting 303(h) ; (2) section 1262 of division FF of Public Law 117–328 is amended— (A) in subsection (a)— (i) in the matter preceding paragraph (1), by striking 303(g) and inserting 303(h) ; (ii) in the matter being stricken by subsection (a)(2), by striking (g)(1) and inserting (h)(1)